3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
44
Lung Neoplasms
9
Brain Neoplasms
7
NSCLC
3
Pancreatic Neoplasms
2
Neoplasms
2
Nasopharyngeal Carcinoma
2
Esophageal Neoplasms
2
EGF-R Positive Non-Small Cell Lung Cancer
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Squamous Cell Carcinoma of Lung
1
Plasma EGFR Mutation-positive Lung Cancer
1
Non-squamous Non-small Cell Lung Cancer
1
Non-small Cell Lung Cancer Metastatic
1
Non-Small-Cell Lung
1
Neuroma, Acoustic
1
Neurofibromatosis 2
1
Neoplasms, Second Primary
1
Neoplasm Metastasis
1
Drug-Related Side Effects and Adverse Reactions
1
Bronchial Neoplasms
1
Breast Neoplasms
1
Interventions
icotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Plasma EGFR Mutation-positive Lung Cancer
×
icotinib
×
Clear all
NCT03346811
2017-11-17
CHALLENGE
Betta Pharmaceuticals Co., Ltd.
Phase 2
Unknown
120 enrolled